login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
BOLT BIOTHERAPEUTICS INC (BOLT) Stock News
USA
-
Nasdaq
- NASDAQ:BOLT -
US0977022039
-
Common Stock
5.31
USD
+0.04 (+0.76%)
Last: 12/4/2025, 8:06:54 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
BOLT Latest News, Press Relases and Analysis
All
Press Releases
22 days ago - By: Zacks Investment Research
- Mentions:
FENC
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Beats Revenue Estimates
22 days ago - By: Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
22 days ago - By: Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update
a month ago - By: Zacks Investment Research
- Mentions:
PTGX
Bolt Biotherapeutics, Inc. (BOLT) Expected to Beat Earnings Estimates: Should You Buy?
2 months ago - By: Benzinga
- Mentions:
SCLX
TSHA
RVPH
PALI
...
12 Health Care Stocks Moving In Thursday's Intraday Session
4 months ago - By: The Motley Fool
Bolt Revenue Jumps 39 Percent in Q2
2 months ago - By: Benzinga
- Mentions:
COOP
WOOF
EFX
RKT
...
Fidus Investment, Rocket Companies And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
2 months ago - By: Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
2 months ago - By: Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027
4 months ago - By: Zacks Investment Research
- Mentions:
ELMD
Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates
4 months ago - By: Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
4 months ago - By: Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
4 months ago - By: Zacks Investment Research
- Mentions:
PHAT
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q2 Loss, Tops Revenue Estimates
7 months ago - By: Zacks Investment Research
- Mentions:
IMNM
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates
7 months ago - By: Zacks Investment Research
- Mentions:
ARCT
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates
7 months ago - By: Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
7 months ago - By: Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
7 months ago - By: Yahoo Finance
- Mentions:
KRYS
JAZZ
HEPA
TECH
Biotech Alert: Searches spiking for these stocks today
7 months ago - By: Zacks Investment Research
- Mentions:
PRTA
Prothena (PRTA) Reports Q1 Loss, Misses Revenue Estimates
7 months ago - By: Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates
7 months ago - By: Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbodyâ„¢ ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025
7 months ago - By: Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
7 months ago - By: Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
8 months ago - By: Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
8 months ago - By: Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
9 months ago - By: Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
9 months ago - By: Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update
9 months ago - By: Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics to Participate in Upcoming March Conferences
10 months ago - By: Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.
10 months ago - By: Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.
a year ago - By: Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
a year ago - By: Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
Please enable JavaScript to continue using this application.